{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T17:06:06Z","timestamp":1745946366541},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,11]]},"DOI":"10.7759\/cureus.50352","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:47:51Z","timestamp":1702342071000},"source":"Crossref","is-referenced-by-count":3,"title":["Use of Interleukin-12\/23 Inhibitor for the Management of Acne Fulminans"],"prefix":"10.7759","author":[{"given":"Hannah","family":"Gier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Israeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Cusick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12983","article-title":"Acne fulminans: case series and review of the literature","volume":"33","author":"Alakeel A","year":"2016","unstructured":"Alakeel A, Ferneiny M, Auffret N, Bodemer C. Acne fulminans: case series and review of the literature. Pediatr Dermatol. 2016, 33:e388-92. 10.1111\/pde.12983","journal-title":"Pediatr Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5070\/D32612051358","article-title":"Acne fulminans induced by a low dose isotretinoin: case report and review of the literature","volume":"26","author":"Fakih A","year":"2020","unstructured":"Fakih A, Goens J, Grozdev I, Dangoisse C, Richert B. Acne fulminans induced by a low dose isotretinoin: case report and review of the literature. Dermatol Online J. 2020, 26:12 . 10.5070\/D32612051358","journal-title":"Dermatol Online J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20176546","article-title":"Acne fulminans","volume":"92","author":"Proen\u00e7a NG","year":"2017","unstructured":"Proen\u00e7a NG. Acne fulminans. An Bras Dermatol. 2017, 92:8-10. 10.1590\/abd1806-4841.20176546","journal-title":"An Bras Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(89)70045-1","article-title":"Bone lesions of acne fulminans: case report and review of the literature","volume":"20","author":"Jemec GB","year":"1989","unstructured":"Jemec GB, Rasmussen I. Bone lesions of acne fulminans: case report and review of the literature. J Am Acad Dermatol. 1989, 20:353-7. 10.1016\/s0190-9622(89)70045-1","journal-title":"J Am Acad Dermatol"},{"key":"ref5","article-title":"Dermatology","author":"Bolognia JL","year":"2012","unstructured":"Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. Bolognia JL, Jorizzo JL, Schaffer JV (ed): Elsevier Saunders, Philadelphia; 2012."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.028","article-title":"Evidence-based recommendations for the management of acne fulminans and its variants","volume":"77","author":"Greywal T","year":"2017","unstructured":"Greywal T, Zaenglein AL, Baldwin HE, et al.. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol. 2017, 77:109-17. 10.1016\/j.jaad.2016.11.028","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.05.018","article-title":"Acne fulminans: a narrative review","volume":"114","author":"Guti\u00e9rrez-Mer\u00e9 R","year":"2023","unstructured":"Guti\u00e9rrez-Mer\u00e9 R, Tajes I, Di\u00e9guez P, Soto-Garc\u00eda D, Mart\u00ednez-Fern\u00e1ndez S, Batalla A. Acne fulminans: a narrative review. Actas Dermosifiliogr. 2023, 114:763-71. 10.1016\/j.ad.2023.05.018","journal-title":"Actas Dermosifiliogr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.855","article-title":"The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder","volume":"148","author":"Kraus SL","year":"2012","unstructured":"Kraus SL, Emmert S, Sch\u00f6n MP, Haenssle HA. The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol. 2012, 148:1210-2. 10.1001\/archdermatol.2012.855","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.51894\/001c.7003","article-title":"A novel treatment of acne fulminans with adalimumab: a case report","volume":"3","author":"Rajaii R","year":"2018","unstructured":"Rajaii R, Globerson J, Arnold N, Mahon M. A novel treatment of acne fulminans with adalimumab: a case report. Spartan Med Res J. 2018, 3:7003. 10.51894\/001c.7003","journal-title":"Spartan Med Res J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1187186","article-title":"Case report: acne vulgaris treatment with 5-Aminolaevulinic acid photodynamic therapy and adalimumab: a novel approach","volume":"10","author":"Ping Y","year":"2023","unstructured":"Ping Y, Jian Bo Z, Xing Yun Z, Ali K, Jun C, Xu Lou I, Wu LM. Case report: acne vulgaris treatment with 5-Aminolaevulinic acid photodynamic therapy and adalimumab: a novel approach. Front Med (Lausanne). 2023, 10:1187186. 10.3389\/fmed.2023.1187186","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.309","article-title":"Propionibacterium acnes Induces IL-1\u03b2 secretion via the NLRP3 inflammasome in human monocytes","volume":"134","author":"Qin M","year":"2014","unstructured":"Qin M, Pirouz A, Kim MH, Krutzik SR, Garb\u00e1n HJ, Kim J. Propionibacterium acnes Induces IL-1\u03b2 secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol. 2014, 134:381-8. 10.1038\/jid.2013.309","journal-title":"J Invest Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020303","article-title":"Cutibacterium acnes as an opportunistic pathogen: an update of its virulence-associated factors","volume":"9","author":"Mayslich C","year":"2021","unstructured":"Mayslich C, Grange PA, Dupin N. Cutibacterium acnes as an opportunistic pathogen: an update of its virulence-associated factors. Microorganisms. 2021, 9:303. 10.3390\/microorganisms9020303","journal-title":"Microorganisms"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00552-6","article-title":"Updated treatment for acne: targeted therapy based on pathogenesis","volume":"11","author":"Kurokawa I","year":"2021","unstructured":"Kurokawa I, Layton AM, Ogawa R. Updated treatment for acne: targeted therapy based on pathogenesis. Dermatol Ther (Heidelb). 2021, 11:1129-39. 10.1007\/s13555-021-00552-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00789-1","article-title":"Targeting inflammation in acne: current treatments and future prospects","volume":"24","author":"Cruz S","year":"2023","unstructured":"Cruz S, Vecerek N, Elbuluk N. Targeting inflammation in acne: current treatments and future prospects. Am J Clin Dermatol. 2023, 24:681-94. 10.1007\/s40257-023-00789-1","journal-title":"Am J Clin Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105238","article-title":"IL-17\/Th17 pathway is activated in acne lesions","volume":"9","author":"Kelh\u00e4l\u00e4 HL","year":"2014","unstructured":"Kelh\u00e4l\u00e4 HL, Palatsi R, Fyhrquist N, et al.. IL-17\/Th17 pathway is activated in acne lesions. PLoS One. 2014, 9:e105238. 10.1371\/journal.pone.0105238","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu T","year":"2020","unstructured":"Liu T, Li S, Ying S, et al.. The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020, 11:594735. 10.3389\/fimmu.2020.594735","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15362","article-title":"Two clinical subtypes with different management of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single centre experience","volume":"35","author":"Falkenhain-L\u00f3pez D","year":"2022","unstructured":"Falkenhain-L\u00f3pez D, S\u00e1nchez-Vel\u00e1zquez A, Fulgencio-Barbarin J, Puerta-Pe\u00f1a M, Ortiz-Romero PL, Postigo-Llorente C, Rivera-D\u00edaz R. Two clinical subtypes with different management of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single centre experience. Dermatol Ther. 2022, 35:e15362. 10.1111\/dth.15362","journal-title":"Dermatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience","volume":"16","author":"Martora F","year":"2023","unstructured":"Martora F, Megna M, Battista T, et al.. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023, 16:135-48. 10.2147\/CCID.S391356","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2014.10.007","article-title":"Successful use of ustekinumab therapy in refractory severe atopic dermatitis","volume":"1","author":"Shroff A","year":"2015","unstructured":"Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 2015, 1:25-6. 10.1016\/j.jdcr.2014.10.007","journal-title":"JAAD Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.05.029","article-title":"Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)","volume":"14","author":"Flora A","year":"2021","unstructured":"Flora A, Holland R, Smith A, Frew JW. Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab). JAAD Case Rep. 2021, 14:33-6. 10.1016\/j.jdcr.2021.05.029","journal-title":"JAAD Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205555-use-of-interleukin-1223-inhibitor-for-the-management-of-acne-fulminans","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:31Z","timestamp":1707509371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205555-use-of-interleukin-1223-inhibitor-for-the-management-of-acne-fulminans"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.50352","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,11]]}}}